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Production and hosting by ElsevierRagab A. Mahfouz a,⇑, Ahmad Alzaiat a, Marwa Gad aa Congenital Unit, Cardiology Department, Zagazig University Hospital
a EgyptObjectives: We evaluated the influence of device closure for patent ductus arteriosus (PDA) on the aortic stiffness
index (ASI) and brain natriuretic peptide (BNP) and their association with cardiac function.
Patients and methods: ASI and echocardiography assessment before and after treatment (16 ± 9 months) in 48 chil-
dren with PDA (mean age 10 ± 4.5) and 52 control children (mean age 9.7 ± 4.6). BNP level was measured pre-closure
for all children, and was measured six months after closure only for children with PDA.
Results: ASI was higher in PDA patients than in controls (P < 0.001). ASI correlated with age (P < 0.05), LVEF%
(P < 0.01), E/E0 (<0.03), pulmonary artery pressure (P < 0.001), and BNP (P < 0.001). ASI andBNP significantly decreased
after closure (P < 0.001). ASI and BNPwere independent predictors for post-closure systolic dysfunction (P < 0.001and
<0.005, respectively). Receiver operating curve (ROC) analysis showed thatASIP 13.5, BNP levelP75 pg/ml andbasal
mean pulmonary artery pressure (PAP)P 23 were powerful predictors for post-closure systolic function.
Conclusion: ASI is significantly associatedwith BNP andbasal PAP in childrenwith PDA.After device closure, aor-
tic distensibility improved significantly andwas associatedwith significant improvement inboth systolic anddiastolic
functions. ASI can be used for monitoring the course of patients with PDA, and may give opportunities for early
intervention.
 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
Keywords: Aortic stiffness, Device closure, Patent ductus arteriosusIntroduction
Patent ductus arteriosus (PDA) causes volumeoverload of the left side of the heart [1] and
predisposes the patient to pulmonary hypertension.
The timing of treatment for congenital heart defectsis based on the hemodynamic and anatomic
situation, with consideration of myocardial cell
adaptation and chamber remodeling. Therefore,
it is important to have multiple methods available
for follow-up. The combination of new imaging
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Abbreviations
PDA Patent ductus arteriosus
BNP brain natriuretic peptide
ASI aortic stiffness index
TDI Tissue Doppler imaging
EDTA Ethylenediaminetetraacetic Acid
AoS Aortic systolic
AOST Aortic strain
RAO right anterior oblique
ADO Amplatzer duct occluder
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natriuretic peptides may allow us to improve the
evaluation of cardiac function and timing of inter-
ventions [2].
Left ventricle (LV) volume overload and com-
pensatory remodeling alters the systolic and dia-
stolic function of the LV as in chronic aortic and
mitral regurgitation [3–5]. These changes are
expected to improve after PDA closure; however,
some patients develop LV systolic dysfunction.
Clinical examination, X-ray chest, ECG, arterial
saturation (upper and lower limbs) and echocardi-
ography are conclusive in assessing operability in
the majority of patients with PDA and pulmonary
hypertension. However, the decision to intervene
is difficult if the examination results are equivocal.
The purpose of this study is to evaluate the asso-
ciation of aortic stiffness with BNP and its relation
to cardiac function before and after transcatheter
closure of the PDA.Patients and methods
Forty-eight consecutive children, who were
planned for transcatheter closure of PDA, were
enrolled in this prospective observational study.
All patients had clinical and/or echocardiographic
evidence of hemodynamically significant PDA.
Patients with silent PDA, PDA not suitable for
percutaneous closure, irreversible pulmonary vas-
cular disease (pulmonary vascular resistance
index, i.e., pulmonary vascular resistance index
(PVRI) >7 WU m2), and those who had associated
hemodynamically significant congenital heart dis-
ease or a significant residual shunt were excluded
from the study. Study approval was obtained from
the ethics committee and written informed con-
sent was obtained from the parents of patients in
all cases. Control subjects were examined once.
They were asymptomatic and showed no abnor-
malities in clinical examination, ECG, or
echocardiography.
Transthoracic 2D echocardiography and tissue
Doppler imaging (TDI) was performed with the
patient in the supine position using GE-Vivid 3
(General Electric, Milwaukee, WI, USA) with 2.5
and 3.5 MHz transducers on outpatient basis at
baseline, one day after the procedure and at fol-
low-up (at least three months after the procedure).
LV systolic dysfunction was defined as a post-
PDA closure absolute in left ventricular ejection
fraction (LVEF) of <50% and/or reduction in LVEF
of P10% from the baseline. For diastolic function
analysis, the mitral inflow signal was acquired
from three cardiac cycles in the apical four-cham-
ber view; the E (early mitral inflow: rapid atrialfilling) and A (late mitral inflow: late atrial filling)
waves were measured, and the E/A ratio was cal-
culated. Mitral annular diastolic velocities in early
diastole (E0) and late diastole (A0) were obtained
by tissue Doppler imaging and E/E0 was calcu-
lated. Anatomic attributes of the ductus were
assessed for size, minimum diameter toward pul-
monary end, shape, orientation of PDA as well as
adequacy of the ampoule on the aortic end. PDA
size was measured in the parasternal short axis
and ductal view. Left atrial and aortic dimensions
were also measured simultaneously.
BNP measurement
All samples were collected by venipuncture into
Ethylenediaminetetraacetic Acid (EDTA) tubes
within two hours of obtaining the baseline echo-
cardiogram for all children in the study and six
months after device closure of PDA (for children
with PDA only). The blood samples were kept at
room temperature and analyzed within four hours
of sampling using the Triage BNP assay (Biosite
Diagnostics). In some cases, the sample was cen-
trifuged and the plasma was frozen for one to
two days at 70C. Before analysis, each tube
was inverted several times to ensure homogene-
ity. The BNP assay was a sandwich immuno-assay
that consisted of a disposable device to which
250 mL of EDTA-anti-coagulated whole blood or
plasma was added. The Triage meter was used
to measure BNP concentration by detecting a fluo-
rescent signal that reflected the amount of BNP in
the sample [6]. The upper limit of the normal lab
reference for BNP was 42 pg/ml [6].
Non-invasive evaluation of aortic stiffness
The transverse displacement of the aortic wall
was measured with commercially available equip-
ment (GE-Vivid 3; General Electric, Milwaukee,
WI, USA), using 2.5 and 3.5 MHz transducers.
After routine conventional echocardiographic
examination, patients were placed in a left mild
recumbent position and the ascending aorta was
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tracings. The aortic diameter was recorded by M-
mode echocardiogram at a level of 3 cm above the
aortic valve. Internal aortic diameters were mea-
sured by means of a caliper in systole and diastole
as the distance between the trailing edge of the
anterior aortic wall and the leading edge of the
posterior aortic wall.
Aortic systolic (AoS) diameter was measured at
the time of full opening of the aortic valve, and
diastolic (AoD) diameter was measured at the
peak of QRS complex of the electrocardiogram.
Five consecutive beats were measured routinely
and were averaged. Measurements were per-
formed by the same investigator; the intra-obser-
ver variability of aortic diameter measurements
was 2.2%. Values obtained were used to calculate
aortic stiffness indices:
Aortic strain (AOST) = systolic diameter
(SD)  diastolic diameter (DD)/diastolic diameter
(DD)/100; Aortic distensibility = (2/aortic strain)/
PP; and elastic modulus E(p) = PP/strain.
Aortic stiffness (b) Index = ln (systolic blood
pressure/diastolic blood pressure)/AOST and aor-
tic distensibility = 2  AOST/pulse pressure (pure
number) [7,8].Cardiac catheterization
Cardiac catheterization was performed for
assessment of pulmonary artery pressure and
shunt quantification. Only venous access was
obtained during the study. PAH was defined as
mean PA pressure >25 mmHg [9]. Angiographic
assessment was performed after crossing the
PDA and placing a pigtail catheter in the descend-
ing thoracic aorta. Angiograms were performed in
standard lateral view for PDA sizing. In selected
cases, right anterior oblique (RAO) view was also
used for better visualization of PDA for insertion
of Amplatzer duct occluder (ADO, AGA Medical
Corporation, Plymouth, MN, USA). The PDA
was crossed from the pulmonary end in all
patients. Amplatzer delivery sheath (AGATable 1. Demographic characteristics of patients with patent ductu
Variables Patients (n = 98)
Age (years) 9.2 ± 5.9
Gender (m/f) 27/25
Weight (kg) 21.8 + 18
Hight (cm) 123.5 ± 59
Heart rate (b/m) 99 ± 12
SBP 139 ± 11.5
DBP 70.5 ± 4.5
PP 68 ± 7
SBP: systolic blood pressure, DBP: diastolic blood pressure; PP: pulse pressuMedical, Plymouth, MN) was introduced from
the venous route over Amplatzer super stiff guide
wire (Boston Scientific, Natick, MA, USA), and
was parked in the descending thoracic aorta.
Device was delivered as per the standard tech-
nique described earlier [10–12]. Aortogram was
done at 10 min after the release to confirm device
position and rule out residual shunt. After device
deployment, echocardiographic assessment was
performed for the device position, descending
thoracic aortic, and left pulmonary artery velocity.
The ductal occluder device was released after
excluding the significant residual shunt and
obstruction in aorta and/or left pulmonary artery.
All cases were followed at three months and six
months thereafter. Aortic stiffness and NT-BNP
were re-assessed after six months. Improvement
in functional class and weight gain were noted.
Patients were evaluated clinically for any evidence
of worsening of pulmonary hypertension. At fol-
low-up echocardiography, the position of the
device was confirmed, and residual shunt, if any,
was noted.Statistical analysis
Analyses were performed with the Statistical
Package for Social Science version 12.01 for Win-
dows (SPSS Inc., Chicago, IL). Correlation
between aortic stiffness and multiple parameters
was examined via Pearson and Spearman correla-
tion coefficients.Results
The mean age for the cohort was 9.2 ± 5.6 years
at intervention, and 65.4% were females. Demo-
graphic data were represented in Table 1. They
were followed for a mean duration of
23 ± 9 months after device closure. The pulmonary
artery systolic pressure was less than 90% of aortic
systolic pressure in all cases. All study patients
had predominantly left-to-right shunt based ons arteriosus and controls.
Controls (n = 52) P value
9.6 ± 6.2 >0.05
17/31 >0.05
22.7 + 19 >0.05
119 ± 51 >0.05
87 ± 11 >0.05
132.5 ± 9.3 >0.05
81.2 ± 3.9 <0.05
50 ± 5 <0.05
re.
Table 3. Pearson’s linear correlation of aortic stiffness index
with different studied parameters in patient with patent ductus
arteriosus.
Parameter Correlation coefficient (r) P value
Age 0.229 <0.05
LV-EF% 0.436 <0.01
E/E0 0.322 <0.03
Baseline-PAP 0.615 <0.001
BNP 0.542 <0.001
LVEF: left ventricular ejection fraction; E/E0: ratio of early mitral flow
velocity to early mitral annular velocity.PAP: pulmonary artery pres-
sure; BNP: brain natriuretic peptide.
Figure 1. Correlation of ASI and baseline pulmonary artery pressure
at the time of device closure of children with PDA.
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limb saturations of >95%.
All 48 patients with PDA underwent percutane-
ous closure with an Amplatzer duct occluder. In
these children, no other heart defects were
observed. Follow-up was available for all patients
over a period of 23 ± 9 months. At the time of post
deployment angiogram, 36 out of 48 patients
showed residual shunt through the device. How-
ever, this disappeared over time and no residual
shunt was seen in any of the patients at the time
of last follow-up, where all the patients were
either asymptomatic or in the New York Heart
Association (NYHA) class I. During the follow-up
period, none of the patients had any progression
in their peak velocities or gradients across the left
pulmonary artery or the aortic isthmus.
Forty-three out of 48 patients had an estimated
mean PAP of 620 mmHg. In the remaining five
cases, though the PAP was estimated at
>20 mmHg, it was significantly lower than the
pre-procedural PAP. None of the patients showed
any evidence of worsening PHT. At the time of the
last follow-up evaluation, all the patients were
either asymptomatic or in the NYHA class I. Dur-
ing the follow-up period, none of the patients had
any progression in their peak velocities or gradi-
ents across the LPA or the aortic isthmus. BNP
level was significantly higher in children with
PDA than in controls (P < 0.0001) before interven-
tion, while this decreased significantly six months
after intervention (P < 0.001), becoming non-sig-
nificant compared to controls (P > 0.05) (Table 2).
Table 3 shows the ASI significantly correlated with
age (P < 0.05), LV-EF% (P < 0.01), E/E0 (P < 0.03),
baseline-PAP (P < P < 0.001) (Fig. 1), and BNP
(P < 0.001) (Fig. 2). Children with PDA had signifi-
cantly higher ASI than controls before occlusion
(P < 0.001). After intervention, ASI decreased sig-
nificantly (P < 0.003), but was still higher than in
controls (P < 0.05) at the six-month follow-up eval-
uation (Table 4).
The mean pre-closure LVEF% of the children
with PDA was 62.7 + 4.25%. The mean 48 h post-
closure LVEF% was 55.2 ± 5.4%; while the mean
LVEF% after six months follow-up was 70.5 + 5.1.
Of the 48 patients, 12 (25%) had a reducedTable 2. Serum level BNP in patients measured at baseline and at
Patients with PDA (N = 4
BNP (pg/ml)-baseline 103 ± 15
BNP (pg/ml) -6 months 39 ± 7
P <0.001
BNP: brain natriuretic peptide.LVEF% post-closure (EF% <50% or decrease
>10% below the pre-closure EF%). Analysis of
patients with reduced EF% showed they had
higher ASI (P < 0.001), BNP levels (P < 0.001),
higher pre-closure mean PAP (P < 0.003), and duct
size (P < 0.005) as compared to those with normal
systolic function (Table 5). The mean time to
normalization of systolic function was determined
at 6 ± 1.8 months. In one patient only, the device
embolized in the descending aorta, and was
successfully snared and re-implanted.
The mean duct size, as determined by either
echocardiography or during intervention, was
8.6 ± 4.1 mm. The mean PDA size was larger6 months’ follow-up, in patients and in controls.
8) Controls (N = 52) P
32 ± 5 <0.0001
32 ± 5 >0.05
Table 4. Two- dimensional echocardiographic findings in control su
and at 6 and 12 months after device closuer.
Controls (n = 52) Patien
Befor
LVEDD mm 31.5 ± 5.6 36.06
LVESD mm 21.9 ± 3.9
LAD mm 18.6 ± 3.0
Ao mm 19.5 ± 2.3
LA/AO 0.95 ± 0.09
LVEF% 75.5 ± 9.1
E cm/s 73.9 ± 8.3
A cm/s 61.2 ± 9.5
E/A 1.43 ± 0.3
E0 cm/s 15.8 ± 2.5 12.3
E/E0 4.9 ± 1.3
Mean PAP
AOST% 12.5 ± 2.3
Distensibility, mmHg1 .103 4.4 ± 1.5
Elastic modulus N/m2 3.9 ± 1.9
Aortic stiffness index 5.6 ± 2.5
P (Significance between patients before closure and controls).
LVEDD: left ventricular enddiastolic diameter; LVESD: left ventricular endsys
mitral flow velocity to early mitral annular velocity; PAP: pulmonary artery
* P (Significance between patients before and after closure).
Table 5. Comparison between children regarding post-closure left v
Preclosure variable Children with immediate
systolic dysfunction (n = 12)
Aortic beta index (b) 21.5 ± 2.9
BNP 127 + 23
PDA size mm 9.8 ± 1.9
LVEF% 45% + 3
Mean PAP mmHg 32 ± 8
E/E0 9.7 ± 2.4
BNP: brain natriuretic peptide; PDA: patent ductus arteriosus’; LVEF: Left ve
early mitral flow velocity to early mitral annular velocity.
Figure 2. Correlation of ASI and NT-proBNP at the time of device
closure of PDA.
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AORTIC STIFFNESS, BNP, PATENT DUCTUS ARTERIOSUS(9.8 ± 1.9 mm) for children who had higher ASI
and elevated levels of NBP as compared to
children with smaller PDA size (5.4 ± 1.2 mm).
All patients were NYHA class II.
In order to identify the factors associated with a
post-closure decrease in the EF% <50% or more
than 10% below the pre-closure EF%, stepwise
multiple linear regression analysis was performed
(Table 6). Univariate stepwise linear regression
analysis showed that age, EF%, E/E0, baseline
PAP, ASI and BNP level were significantly associ-
ated with LV systolic dysfunction at post-closure
examination. Among these parameters, the ASI
and BNP were statistically significant factors on
multivariate stepwise linear regression analysis
for post-closure LV systolic dysfunction
(P < 0.001and <0.005 respectively).bjects and in groups of children with PDA measured at baseline
ts with PDA (n = 48) P value
e closure After closure P P*
+ 7.4 34.9 ± 5.4 <0.001 <0.01
26.7 ± 5.3 22.9 ± 3.3 <0.001 <0.001
24.7 ± 3.5 20.6 ± 3.8 <0.006 <0.03
24.2 ± 3.1 20.5 ± 4.2 <0.02 <0.02
1.01 ± 0.11 0.98 ± 0.09 >0.05 >0.05
62.7 ± 4.25 70.5 ± 5.1 <0.004 <0.009
88.3 ± 12.5 76.9 ± 9.2 <0.05 <0.05
66.5 ± 9.8 65.2 ± 9.1 >0.05 >0.05
1.41 ± 0.3 1.23 ± 0.3 >0.05 >0.05
+ 3.2 14.8 ± 2.5 >0.05 >0.05
7.8 ± 1.2 5.4 ± 1.3 <0.05 <0.05
38.2 ± 5.3 18.5 ± 4.2 <0.001 <0.0003
8.1 ± 2.2 10.6 ± 2.0 <0.001 <0.005
3.1 ± 1.4 3.8 ± 0.5 <0.01 <0.01
6.5 ± 2.4 4.1 ± 0.9 <0.01 <0.02
17.5 ± 4.1 6.9 ± 1.2 <0.001 <0.001
tolic diameter; LVEF: left ventricular rjection fraction; E/E0: ratio of early
pressure; AOST: aortic strain.
entricular systolic function.
Children with normal
zsystolic function (n = 36)
P value
13.6 ± 2.8 <0.001
81 + 14 <0.001
5.4 ± 1.2 <0.005
65% + 4 <0.002
17.2 ± 5 <0.003
6.2 ± 1.8 <0.02
ntricular rjection fraction; PAP: pulmonary artery pressure; E/E0: ratio of
Table 6. Multiple linear regression analysis for left ventricular
dysfunction at post-closure.
Univariate Multivariate
Pre-closure variables r P value r P value
Age (years) 0.346 <0.05 0.115
LVEF% 0.464 <0.02 0.137
E/E0 0.397 <0.03 0.192
Baseline-PAP (mmHg) 0.513 <0.001 0.210
ASI (B) 0.562 <0.001 0.516 <0.001
BNP (Pg/ml) 0.541 <0.001 0.509 <0.005
LVEF: Left ventricular rjection fraction; E/E0: ratio of early mitral flow
velocity to early mitral annular velocity; PAP: pulmonary artery pres-
sure; ASI: aortic stiffness index; BNP: brain natriuretic peptide.
Table 7. ROC curve of variables for postclosure LVEF.
Area under
ROC
Sensitivity
(%)
Specificity
(%)
Aortic beta
index P
0.95 86 91
BNP P 0.93 84 89
Mean PAP
P33 mmHg
0.811 79 82
LVEF 6 55% 0.92 83 87
BNP: brain natriuretic peptide; pulmonary artery pressure; LVEF: left
ventricular ejection fraction.
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curve for ASI was 0.95, and pre-closure ASI
(P13.5) showed a sensitivity of 86% and specificity
of 91% in predicting the post-closure normal LV
systolic dysfunction. Pre-closure BNP P75 pg/ml
showed a sensitivity of 82% and specificity of
85%; mean PAP P33 mmHg showed a sensitivity
of 79% and specificity of 82%; and pre-closure
LVEF 655% showed a sensitivity of 85% and spec-
ificity of 89% in predicting the immediate post-clo-
sure normal LV systolic function.Discussion
The main findings in the current study are: (1)
Aortic stiffness was significantly increased in chil-
dren with PDA; (2) ASI was positively correlated
with pre-closure LVEF%, BNP, E/E0 ratio, basal
PAP and age; and (3) aortic stiffness decreased
significantly after device closure of PDA, with
associated significant decrease in the level of
BNP with improvement of both systolic and dia-
stolic functions.
The timing of treatment for congenital heart
defects is based on the hemodynamic and anatomic
situation, with consideration of myocardial cell
adaptation and chamber remodeling. Therefore, it
is important to have multiple methods available
for follow-up. We hypothesized that the biophysi-cal properties of the aorta are abnormal in patients
with PDA, and increased arterial stiffness is an
additional factor responsible for the development
of late ventricular failure in those patients.
Given that evidence of patent ductus arteriosus
is usually associated with hyperdynamic status
and that there is a vascular shunt between the
aorta and pulmonary artery, intrinsic aortic
changes occur (aortic stiffness). Moreover, shunt
lesions may be associated with an inflammatory
process, and endothelial dysfunction may
accelerate the aging of vessels, especially the aorta
(aortic stiffness) [13].
Hemodynamic changes, oxygen saturation
changes (nocturnal hypoxemia) due to rise of pul-
monary artery pressure, in addition to the inflam-
matory profile and endothelial dysfunction, may
be the underlying mechanisms of aortic stiffness
in shunt lesions [14,15].
Outcome after closure of a large PDA is deter-
mined primarily by age at the time of repair and
pre-operative pulmonary vascular disease [16].
Age is an important predictor of pulmonary vascu-
lar disease. It is generally agreed that children
under one year of age are unlikely to have irrevers-
ible PAH, and most agree that irreversibility starts
as early as one to two years of age. This generaliza-
tion has some limitations as the pathogenesis of
irreversible PAH and its progression is multifacto-
rial and unpredictable. Blount and associates [17].
indicated that a PDA may have a more marked
effect on the pulmonary circulation than on a ven-
tricular septal defect, and that irreversible pulmon-
ary vascular changes may occur under two years of
age. This is probably the result of the high-pres-
sure pulsatile flow transmitted from the aorta to
the PA throughout the cardiac cycle in PDA.
At the level of the ascending aorta the results
may differ and aortic stiffness in patients with
PDA could be higher than in matched control sub-
jects, considering the possible damage to the endo-
thelium due to turbulent flow transmitted from the
PDA. This could also explain the improvement of
aortic stiffness after device closure of PDA. This
improvement in aortic stiffness could contribute
to the reverse remodeling of left ventricle.
BNP levels were higher in patients with PDA than
in controls at baseline. The peptide level was ele-
vated 4.3 ± 2 months after treatment, and
decreased thereafter. At the six-month follow-up
evaluation, the dimensions of the originally over-
loaded ventricle in patients with PDA had
normalized.
Studies show that a day after PDA occlusion,
serum levels of NT-proBNP increase, but decrease
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levels of NT-proBNP in patients with PDA and
volume overload of LV are in accordance with
the previous studies [18,19]. To our knowledge,
there are no published reports of a correlation
between ASI and peptide levels in patients with
left-sided volume overload caused by PDA. In
our patients with PDA, a significant correlation
was found between serum levels of BNP and the
aortic stiffness index. Plasma levels of BNP have
been demonstrated to correlate with systolic right
ventricle (RV) pressure in children with volume
overload of RV [20]. Plasma levels of BNP have
been shown to correlate with right atrial and ven-
tricular pressures in a child population consisting
of different loading conditions and a wide age
range [21].
Once closed, hemodynamically significant PDA
decreases the preload to the LV by abolishing
the left-to-right shunt, and increases the afterload
by isolating the low-resistance pulmonary circula-
tion from LV outflow circulation. This simulta-
neous reduction in the LV preload and increase
in the afterload may lead to LV systolic dysfunc-
tion. Despite similar hemodynamic changes in
patients with PDA, LV systolic dysfunction is not
a universal feature. Similar LV systolic dysfunc-
tion has been documented in the postoperative
period of mitral regurgitation surgeries [3,4]. The
incidence and predictors of post-PDA closure
and LV systolic dysfunction have been reported
in recent studies [22–24]. Prior studies have shown
that subjects with PDA have higher LVESVI and
LVEDVI, lower LVEF, and higher N-terminal
brain natriuretic peptide (BNP) compared to con-
trols. These changes are documented as resolved
over a six-month follow-up period after percuta-
neous PDA closure [18].
It is important to note that a small percentage of
patients with borderline hemodynamic data with
PDA and PAH can deteriorate after PDA closure
due to non regression of pulmonary hypertension
and progressive PVD and right heart failure after
PDA closure, and their natural history is then sim-
ilar to primary or idiopathic PAH. These patients
have a more favorable natural history if PDA is
left untreated. A foolproof investigation to identify
who may benefit from PDA closure with long-
term regression of PAH, and who may worsen
with progressive pulmonary vascular disease
and right heart failure is currently not available.
Future research on the type and extent of morpho-
logical changes in the pulmonary vessels, individ-
ual variability and correlation with genetic and
epigenetic factors may give a clue to this vexingissue. Until such time, in clinical practice, an occa-
sional patient who will not benefit from closure of
a large PDA may have PDA closure with an
adverse outcome and others without an adverse
outcome.
Limitation
The most significant limitation to this study is
that the number of patients is small. However,
the age range among patient groups and controls
is wide.
Clinical relevance
We have demonstrated that LVEF%, baseline
sPAP and E/E0 ratio remain in correlation with
noninvasive measurement of arterial stiffness in
patients with PDA. The association of elevated
BNP and increased arterial stiffness and therefore
elevated cardiovascular risk are important in the
assessment of early intervention for patients with
congenital shunt lesions such as PDA. It has been
postulated that screening tests that could identify
earlier stages of cardiac dysfunction development
would be of great value. The combination of non-
invasive measurements of arterial stiffness and
BNP level as predictors of systolic dysfunction
could be helpful in the comprehensive care of
patients.
Conclusion
Aortic stiffness is significantly elevated and
associated with higher BNP levels in patients with
PDA. After device closure, ASI decreased signifi-
cantly and was associated with significant
decrease in BNP levels. These changes were asso-
ciated with significantly improved systolic func-
tion months after device closure. ASI might be
useful for monitoring the course of patients with
PDA before and after intervention.
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